Osimertinib plus chemotherapy versus osimertinib for patients with advanced NSCLC with concomitant EGFR and TP53 mutations: a prospective cohort study

Abstract Osimertinib is the standard first-line options for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC). Co-mutations in TP53 results in poor survival for patients. However, the studies on treatment options and clinical outcomes of patients with EGFR-TP53 co- mutation are...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Jixian Li, Xiang Zhan, Mengqing Shao, Renya Zeng, Jianan Li, Hui Zhu, Alei Feng, Zhe Yang, Wang Jing
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Nature Portfolio 2025-07-01
Цуврал:	Scientific Reports
Нөхцлүүд:	NSCLC Osimertinib EGFR TP53 Chemotherapy
Онлайн хандалт:	https://doi.org/10.1038/s41598-025-03422-9
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!